Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-03 5:00 pm Sale | 2026-02-27 | 13D | VIR BIOTECHNOLOGY INC VIR | ARCH Venture Fund IX, L.P. | 13,534,704 8.500% | -17,606 (-0.13%) | Filing History |
| 2025-11-14 4:30 pm Purchase | 2025-09-30 | 13G | LYELL IMMUNOPHARMA INC LYEL | ARCH Venture Fund IX, L.P. | 2,759,072 13.000% | 929,186 (+50.78%) | Filing History |
| 2025-11-14 4:30 pm Purchase | 2025-09-30 | 13G | SANA BIOTECHNOLOGY INC SANA | ARCH Venture Fund IX, L.P. | 46,093,125 17.300% | 65,000 (+0.14%) | Filing History |
| 2025-05-15 5:05 pm Sale | 2025-02-21 | 13G | SINGULAR GENOMICS SYS INC OMIC | ARCH Venture Fund IX, L.P. | 0 0.000% | -126,711 (Position Closed) | Filing History |
| 2025-05-15 5:04 pm Unchanged | 2025-03-31 | 13G | BEAM THERAPEUTICS INC BEAM | ARCH Venture Fund IX, L.P. | 4,600,747 4.600% | 0 (Unchanged) | Filing History |
| 2025-02-14 4:55 pm Purchase | 2024-12-31 | 13G | LYELL IMMUNOPHARMA INC LYEL | ARCH Venture Fund IX, L.P. | 1,829,886 13.100% | 6,000 (+0.33%) | Filing History |
| 2025-02-14 4:55 pm Sale | 2024-12-31 | 13G | BEAM THERAPEUTICS INC BEAM | ARCH Venture Fund IX, L.P. | 4,600,747 5.600% | -902,907 (-16.41%) | Filing History |
| 2024-11-14 5:12 pm Purchase | 2024-09-30 | 13G | SANA BIOTECHNOLOGY INC SANA | ARCH Venture Fund IX, L.P. | 46,028,125 20.600% | 1,883,181 (+4.27%) | Filing History |
| 2024-10-29 6:32 pm Purchase | 2024-04-02 | 13D | BOUNDLESS BIO, INC. BOLD | ARCH Venture Fund IX, L.P. | 2,699,970 12.100% | 2,699,970 (New Position) | Filing History |
| 2024-02-14 3:18 pm Purchase | 2023-12-31 | 13G | LYELL IMMUNOPHARMA INC LYEL | ARCH Venture Fund IX, L.P. | 1,823,886 14.500% | 3,250 (+0.18%) | Filing History |
| 2024-02-14 3:18 pm Sale | 2023-12-31 | 13G | BEAM THERAPEUTICS INC BEAM | ARCH Venture Fund IX, L.P. | 5,503,654 6.800% | -367,496 (-6.26%) | Filing History |
| 2024-02-09 5:35 pm Purchase | 2023-12-31 | 13G | SANA BIOTECHNOLOGY INC SANA | ARCH Venture Fund IX, L.P. | 44,144,944 22.400% | 65,536 (+0.15%) | Filing History |
| 2024-02-09 5:35 pm Sale | 2023-07-24 | 13G | GOSSAMER BIO INC GOSS | ARCH Venture Fund IX, L.P. | 0 0.000% | -8,055,916 (Position Closed) | Filing History |
| 2023-02-13 4:07 pm Purchase | 2022-12-31 | 13G | SANA BIOTECHNOLOGY INC SANA | ARCH Venture Fund IX, L.P. | 44,079,408 23.100% | 817 (+0.00%) | Filing History |
| 2022-09-20 4:58 pm Sale | 2022-08-12 | 13D | KARUNA THERAPEUTICS INC KRTX | ARCH Venture Fund IX, L.P. | 0 0.000% | -2,946,891 (Position Closed) | Filing History |
| 2022-09-13 3:45 pm Sale | 2022-08-12 | 13D | VIR BIOTECHNOLOGY INC VIR | ARCH Venture Fund IX, L.P. | 13,552,310 10.200% | -5,636,784 (-29.37%) | Filing History |
| 2022-05-10 5:05 pm Purchase | 2021-12-20 | 13D | VIR BIOTECHNOLOGY INC VIR | ARCH Venture Fund IX, L.P. | 19,189,094 14.700% | 3,374 (+0.02%) | Filing History |
| 2022-02-14 12:04 pm Sale | 2021-12-31 | 13G | BEAM THERAPEUTICS INC BEAM | ARCH Venture Fund IX, L.P. | 5,871,150 8.600% | -2,371,889 (-28.77%) | Filing History |
| 2022-02-14 12:04 pm Purchase | 2021-12-31 | 13G | LYELL IMMUNOPHARMA INC LYEL | ARCH Venture Fund IX, L.P. | 1,820,636 15.100% | 1,820,636 (New Position) | Filing History |
| 2022-02-10 5:12 pm Purchase | 2021-12-31 | 13G | SANA BIOTECHNOLOGY INC SANA | ARCH Venture Fund IX, L.P. | 44,078,591 23.300% | 44,078,591 (New Position) | Filing History |